Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study-Reference-Cited by-同舟云学术

Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study

Published:2022-01-10 Issue:1 Volume:11 Page:283-301
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Cong Duanduan,Song Jie,Liu Yue,Tan Yan,Xue Wei,Liu Xiaohui,Qi Wenyuan,Lu Jun,Yuan Xiaojuan,Zhou Yongchun,Hui Ai-Min,Li Kexin

Funder

Wanbang Biopharmaceuticals Co., Ltd.

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-021-00314-8.pdf

Reference30 articles.

1. Schapira AHV, Emre M, Jenner P, Poewe W. Levodopa in the treatment of Parkinson’s disease. Eur J Neurol. 2009;16:982–9.

2. Agid Y, Ahlskog E, Albanese A, et al. Levodopa in the treatment of Parkinson’s disease: a consensus meeting. Mov Disord. 1999;14:911–3.

3. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov Disord. 2004;19:997–1005.

4. Gershanik OS. Improving L-dopa therapy: the development of enzyme inhibitors. Mov Disord. 2015;30:103–13.

5. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the “wearing off” phenomenon and levodopa requirements in fluctuating parkinsonian patients. Neurology. 1998;50:S46-53.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro effects of opicapone on activity of human UDP-glucuronosyltransferases isoforms;Toxicology Letters;2022-08